Protocol summary

Summary
The aim of this study is to investigate the effect of ascorbic acid Add-On compared to Haloperidol alone in schizophrenia. A total of 50 patients with schizophrenia admitted to Zare hospital of Sari are randomly assigned into intervention or control group to receive haloperidol 15-30 mg/day plus ascorbic acid 400 mg/day or the same dose of haloperidol plus placebo for 6 weeks. Psychotic symptoms are assessed weekly by Positive and Negative Syndrome Scale for 6 weeks.

General information

Acronym
IRCT registration information
IRCT registration number: IRCT138809201457N7
Registration date: 2010-11-02, 1389/08/11
Registration timing: retrospective

Last update:
Update count: 0
Registration date
2010-11-02, 1389/08/11
Registrant information
Name
Mehran Zarghami
Name of organization / entity
Research Center for Psychiatry and Behavioral Sciences and Department of Psychiatry, Mazandaran Univ
Country
Iran (Islamic Republic of)
Phone
+98 15 1328 5659
Email address
mzarghami@mazums.ac.ir
Recruitment status
Recruitment complete
Funding source
Mazandaran University of Medical Sciences
Expected recruitment start date
2003-04-03, 1382/01/14
Expected recruitment end date
2006-08-03, 1385/05/12
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Beneficial Antipsychotic Effects of Ascorbic Acid Add-On Therapy Compared to Halloperidol Alone in Schizophrenia, (A Randomized, Double-blind, Placebo-Controlled Clinical Trial)
Public title
Beneficial Antipsychotic Effects of Ascorbic Acid Add-On Therapy Compared to Halloperidol Alone in Schizophrenia, (A Randomized, Double-blind, Placebo-Controlled Clinical Trial)
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria: DSM-IV-TR criteria for schizophrenia, Informed consent of the patients and their tutor, living in the southern coastwise of the Caspian sea, Hospitalization in Zare Hospital Exclusion criteria: Treatment resistance schizophrenia
Age
From 18 years old to 65 years old
Gender
Both
Phase
4
Groups that have been masked
No information
Sample size
Target sample size: 40
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committeee of Mazandaran University of Medical Sciences
Street address
Moallem Square
City
Sari
Postal code
4817844718
Approval date
2002-07-02, 1381/04/11
Ethics committee reference number
31-81

Health conditions studied

1

Description of health condition studied
Schizophrenia
ICD-10 code
F20
ICD-10 code description
Schizophrenia

Primary outcomes

1

Description
Symptoms of schizophrenia
Timepoint
weekly
Method of measurement
Brief Psychiatric Rating Scale (BPRS)

Secondary outcomes

1

Description
Faster response to haloperidol and side effects
Timepoint
weekly
Method of measurement
Brief Psychiatric Rating Scale (BPRS) and clinical interview and examination

Intervention groups

1

Description
Haloperidol, 20 mg/day, orally, plus Ascorbic acid, 1500 mg/day, for 6 weeks, Biperiden (up to 6 mg/day) and lorazepam tablets were available for extra-pyramidal side effects and agitation or anxiety respectively
Category
Treatment - Drugs

2

Description
Haloperidol, 20 mg/day, orally, plus Placebo, for 6 weeks, Biperiden (up to 6 mg/day) and lorazepam tablets were available for extra-pyramidal side effects and agitation or anxiety respectively
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Zare Hospital
Full name of responsible person
Mehran Zarghami
Street address
Zare Hospital, Neka Road
City
Sari

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Seyed Jalal Hoseini Mehr
Street address
Moallem Square
City
Sari
Grant name
10506
Grant code / Reference number
31-81
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mazandaran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Mehran Zarghami
Position
Professor
Other areas of specialty/work
Street address
Zare Hospital, Neka Road
City
Sari
Postal code
4815466848
Phone
+98 15 1328 5659
Fax
+98 15 1328 5109
Email
mzarghami@mazums.ac.ir & mehran.zarghami@gmail.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Mehran Zarghami
Position
Professor
Other areas of specialty/work
Street address
Zare Hospital, Neka Road
City
Sari
Postal code
4815466848
Phone
+98 15 1328 5659
Fax
+98 15 1328 5109
Email
mzarghami@mazums.ac.ir & mehran.zarghami@gmail.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Mehran Zarghami
Position
Professor
Other areas of specialty/work
Street address
Zare Hospital, Neka Road
City
Sari
Postal code
4815466848
Phone
+98 15 1328 5659
Fax
+98 15 1328 5109
Email
mzarghami@mazums.ac.ir & mehran.zarghami@gmail.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty
Loading...